Ramkumar Mandalam
Director/Board Member bei CRYOPORT, INC.
Vermögen: 620 951 $ am 31.03.2024
Profil
Ramkumar Mandalam is the founder of Citra Bioconsulting, Inc. (founded in 2021) and currently holds the position of Chief Executive Officer.
He is also currently working as the President, Chief Executive Officer & Director at Cellerant Therapeutics, Inc. since 2005.
Additionally, he serves as an Independent Director at CryoPort, Inc. since 2014 and as a Director at Stempeutics Research Pvt.
Ltd.
Dr. Mandalam previously worked as the Executive Director-Product Development at Geron Corp.
and as the Director-Developmental Research at Vericel Corp.
from 1994 to 2000.
He obtained a doctorate degree from the University of Michigan.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CRYOPORT, INC.
0,07% | 18.03.2024 | 35 082 ( 0,07% ) | 620 951 $ | 31.03.2024 |
Aktive Positionen von Ramkumar Mandalam
| Unternehmen | Position | Beginn |
|---|---|---|
| CRYOPORT, INC. | Director/Board Member | 16.06.2014 |
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Chief Executive Officer | 01.01.2005 |
Stempeutics Research Pvt. Ltd.
 Stempeutics Research Pvt. Ltd. Pharmaceuticals: MajorHealth Technology Stempeutics Research Pvt. Ltd. is a clinical-stage biotech company based in Bangalore, India. The private company was founded in 2006 by Manipal Education and Medical Group (MEMG) and has since formed strategic alliances with Cipla in 2009 and with Kemwell in 2019. Stempeutics specializes in developing innovative stem cell products through cutting-edge research and clinical applications. Its highly qualified team is dedicated to developing novel cell therapy drugs to address major unmet medical needs with a first-next approach. | Director/Board Member | - |
| Citra Bioconsulting, Inc. | Chief Executive Officer | 01.01.2021 |
Ehemalige bekannte Positionen von Ramkumar Mandalam
| Unternehmen | Position | Ende |
|---|---|---|
| VERICEL CORPORATION | Chief Tech/Sci/R&D Officer | 01.01.2000 |
| GERON CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Ramkumar Mandalam
| University of Michigan | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GERON CORPORATION | Health Technology |
| VERICEL CORPORATION | Health Technology |
| CRYOPORT, INC. | Transportation |
| Private Unternehmen | 3 |
|---|---|
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Stempeutics Research Pvt. Ltd.
Stempeutics Research Pvt. Ltd. Pharmaceuticals: MajorHealth Technology Stempeutics Research Pvt. Ltd. is a clinical-stage biotech company based in Bangalore, India. The private company was founded in 2006 by Manipal Education and Medical Group (MEMG) and has since formed strategic alliances with Cipla in 2009 and with Kemwell in 2019. Stempeutics specializes in developing innovative stem cell products through cutting-edge research and clinical applications. Its highly qualified team is dedicated to developing novel cell therapy drugs to address major unmet medical needs with a first-next approach. | Health Technology |
| Citra Bioconsulting, Inc. |
